Noninvasive Positive-Pressure Ventilation for Preeclampsia-Induced Pulmonary Edema: 3 Case Reports and a Literature Review by Hamada, Kohei et al.
Title
Noninvasive Positive-Pressure Ventilation for Preeclampsia-
Induced Pulmonary Edema: 3 Case Reports and a Literature
Review
Author(s)
Hamada, Kohei; Chigusa, Yoshitsugu; Kondoh, Eiji; Ueda,
Yusuke; Kawahara, Shunsuke; Mogami, Haruta; Horie,
Akihito; Baba, Tsukasa; Mandai, Masaki




© 2018 Kohei Hamada et al. This is an open access article
distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction





Noninvasive Positive-Pressure Ventilation for
Preeclampsia-Induced Pulmonary Edema: 3 Case Reports and
a Literature Review
Kohei Hamada, Yoshitsugu Chigusa , Eiji Kondoh, Yusuke Ueda, Shunsuke Kawahara,
Haruta Mogami, Akihito Horie, Tsukasa Baba, andMasaki Mandai
Department of Gynecology and Obstetrics, Kyoto University, 54 Shogoin Kawahara-cho, Sakyo-ku, Kyoto 606-8507, Japan
Correspondence should be addressed to Yoshitsugu Chigusa; chigusa@kuhp.kyoto-u.ac.jp
Received 12 April 2018; Accepted 7 August 2018; Published 15 August 2018
Academic Editor: Maria Grazia Porpora
Copyright © 2018 Kohei Hamada et al.This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Pulmonary edema caused by severe preeclampsia can be an indication for pregnancy termination. We aimed to investigate
whether noninvasive positive-pressure ventilation (NPPV) was useful for preeclampsia-induced pulmonary edema. Three cases
of preeclampsia-induced pulmonary edemamanaged with NPPV in our institute were reviewed retrospectively. A literature review
was conducted regardingNPPVusage during pregnancy.NPPVwas initiated at 30, 20, and 24weeks of gestation in the 3 cases. In all
cases, NPPV slowed the progression of pulmonary edema and succeeded in delaying pregnancy termination by 17 days on average.
Maternal outcomes were positive, and no intubation was required. Between 1994 and 2017, there were 11 articles describing 12 cases
in which NPPV was applied for pulmonary edema during pregnancy. However, there has been no case of NPPV management of
preeclampsia-inducedpulmonary edema thus far.Maternal and fetal outcomeswere positive in these 12 cases.NPPVmay contribute
to prolonging pregnancy in patients with poor oxygenation due to preeclampsia-induced pulmonary edema. However, patients
should be closely monitored, and the decision to intubate or terminate the pregnancy should be made without delay when the
maternal or fetal condition worsens.
1. Introduction
Preeclampsia, which complicates 3-5% of pregnancies, is still
a leading cause ofmaternal and neonatalmortality. Currently,
the only definitive remedy is to deliver the baby and the pla-
centa [1]. Pulmonary edema is a life-threatening complication
of preeclampsia, and once it occurs, pregnancy termination
is indicated. Considering the mortality and morbidity of
neonates, however, obstetricians are tasked with the critical
decision of whether to perform an extreme preterm delivery
(< 28 weeks of gestation).
Noninvasive positive-pressure ventilation (NPPV) is a
form of noninvasive ventilation (NIV), and it refers to
the delivery of assisted mechanical ventilation without an
invasive endotracheal airway. NPPV employs a full facial
mask or nasal cannula that conducts gas from a positive-
pressure ventilator into the airways. NPPV has been widely
used in patients with chronic respiratory failure, and it has
been increasingly applied to patients with various forms of
acute respiratory failure [2, 3]. However, few studies have
investigated the efficacy of NPPV during pregnancy, and
reports describing NPPVmanagement for pulmonary edema
due to preeclampsia are scarce.
We herein report three cases of hypoxemic respira-
tory failure due to pulmonary edema induced by severe
preeclampsia that were successfully managed with NPPV.We
also review the relevant literature on NPPV usage during
pregnancy, especially in the context of preeclampsia-induced
pulmonary edema.
2. Case 1
A 21-year-old woman pregnant with twins at 29 weeks of
gestation was admitted to the previous hospital for preterm
labor. After one week of tocolysis with intravenous rito-
drine, she developed acute dyspnea and was referred to our
hospital. Ritodrine was stopped immediately, and computed
tomography of the chest revealed no pulmonary embolus, but
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bilateral pleural effusion was present. On admission, she also
presentedwith hypertension (152/112mmHg) and proteinuria
(3.8 g/day). She was diagnosed with severe preeclampsia,
andmagnesium sulfate was initiated, and betamethasone was
administered for accelerating fetal lung maturation. After
starting magnesium sulfate, her systolic blood pressure did
not exceed 140mmHg, and no further antihypertensive agent
was necessary. On day 3 of admission, her SpO
2
fell to 95%
with 5 liters of supplemental oxygen, and NPPV was initi-
ated. After implementation of NPPV, her subjective dyspnea
improved, and her SpO
2
rose to 99% on room air. Pulmonary
edema was also ameliorated on her chest X-ray. However,
her serum creatinine level was increased to 1.0 mg/dl at
33 weeks of gestation, indicating reduced kidney function.
Other symptoms, such as increase in liver enzymes, platelet
reduction, and gastrointestinal or neurological symptoms,
were not detected. Fetal conditions in utero were favorable.
She underwent a cesarean section at 33 weeks and 1 day
of gestation due to initiation of labor. The patient delivered
healthy male twin infants weighing 1496 g and 1876 g. NPPV
was continued intermittently after delivery until she was
successfully weaned off of it.
3. Case 2
A 36-year-old primigravida at 17 weeks and 4 days of
gestation was admitted for hypertension (152/99 mmHg),
proteinuria (1.8 g/day), and elevated liver enzymes (AST
75 U/L, ALT 121 U/L). Careful examination revealed no
evidence of secondary hypertension or primary renal disease.
Furthermore, serum levels of soluble fms-like tyrosine kinase
1 (sFlt1) were very high (8.41 ng/mL) at 18 weeks of gesta-
tion. Subsequently, we classified this case as extremely early
onset preeclampsia [4]. Nifedipine and magnesium sulfate
were administered. Ascites, pleural effusion, and pulmonary
edema were detected at 19 weeks of gestation. NPPV was
initiated for worsening pleural effusion at 20 weeks of
gestation due to desaturation (94% SpO
2
on room air).
After NPPV implementation, the patient’s SpO
2
rose to 99%
with 1 liter of supplemental oxygen. Chest X-ray showed no
progression of pulmonary edema, although ascites gradually
increased, resulting in an emergency cesarean section at 23
weeks and 3 days of gestation due to deteriorating dyspnea,
and nonreassuring fetal status, specifically reversed end-
diastolic umbilical artery flow and absence of atrial-flow in
ductus venosus. A 285 gmale infant was delivered. NPPVwas
discontinued on day 2 after delivery.
4. Case 3
A 40-year-old primigravida at 24 weeks of gestation was
referred to our hospital for severe hypertension (170/95
mmHg) and proteinuria (8.8 g/day). On admission, she
received magnesium sulfate, methyldopa, and nifedipine. On
day 2 of admission, she developed respiratory distress with
mild desaturation (95% SpO
2
on room air), and chest X-
ray showed bilateral pleural effusion. Blood exam revealed
elevation of liver enzymes (AST 133 U/L, ALT 161 U/L),
and partial HELLP syndromewas diagnosed. Corticosteroids
were administered intravenously, and NPPV was initiated.
The patient’s SpO
2
rose to 99%, and pleural effusion did
not increase further. However, ascites gradually increased,
and her general fatigue became intolerable. As a result, a
cesarean section was performed at 25 weeks and 2 days
of gestation. Before delivery, the fetal condition in utero
was reassuring, in terms of fetal heart rate monitoring and
biophysical profile score. A 532 g female baby was delivered.
We applied NPPVpostoperatively, and she was discharged on
day 12 after delivery without any complications.
5. Methods of Literature Review
A literature review was conducted by searching PubMed for
cohort studies or case series using the terms “non-invasive
ventilation” AND “pregnancy” between 1994 and 2017. The
articles eligible for the study included primary studies that
reported clinical data on NPPV usage during pregnancy
or parturition. Thirty-five articles including 154 cases were
extracted for the final assessment (Figure 1), and 11 of these
articles described 12 cases in which NPPVwas applied due to
pulmonary edema (Table 2).
6. Discussion
To the best of our knowledge, this study presents the first
cases of pulmonary edema due to preeclampsia that were
successfully managed with NPPV during pregnancy. By ini-
tiating NPPV before parturition, we succeeded in extending
gestation by an average of 17 days (Table 1). This increase in
gestational timemay lead to better neonatal health outcomes.
Pulmonary edema occurs in approximately 2.9% of
patients with preeclampsia [5]. The recent case control study
showed that the rate of cesarean delivery was significantly
higher among preeclamptic women with pulmonary edema
(71.1%) than among those who did not have pulmonary
edema (47%). Further, more than 80% of patients with
pulmonary edema require mechanical ventilation [6].
In addition, the negative effect of pulmonary edema on
preeclampsiamay be associatedwith highmaternalmortality,
even though this association was not statistically significant
[6]. Thus, acute respiratory failure due to pulmonary edema
could be a factor influencing the decision for pregnancy
termination. For example, the American Congress of Obste-
tricians and Gynecologists strongly recommends delivery
irrespective of gestational age for preeclamptic womenwhose
condition is complicated with pulmonary edema [7]. How-
ever, early preterm delivery, especially at less than 28 weeks of
gestation, is associatedwith highneonatalmortality andmor-
bidity. Moreover, neonates born to mothers with early onset
preeclampsia have highermortality, a lower birth weight, and
more neonatal complications than gestational age-matched
premature neonates born with other etiologies [8].Therefore,
in cases of preeclampsia-induced pulmonary edema early in
gestation, we conclude that managing pulmonary edema and
hypertension to prolong the gestational period may strongly
impact neonatal outcomes.
NPPV comprises continuous positive airway pressure
(CPAP) and bilevel positive airway pressure (BiPAP) and
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Table 2: NPPV management of pulmonary edema during pregnancy.





Mazlan 2017 Pneumonia 32 weeks of gestation 3 days
Gibbs 2016 TRALI 28 weeks of gestation 24 hours
Fujita 2014 Tocolytic agent During CS 22 hours after CS
Allred 2013 Pneumonia 30 weeks of gestation 2 days
28 weeks of gestation 3 days
Suarez 2011 Preeclampsia After CS 3 days
Frassanito 2011 ARDSdue to sepsis After CS 12 hours





23 weeks of gestation 10 days
Banga 2009 ARDSdue to pneumonia N / A 3-4 days
Perbet 2008 Tocolytic agent During labor NA
Terajima 2006 Preeclampsia During CS NA
NPPV: noninvasive positive pressure ventilation. TRALI: transfusion-related acute lung injury. ARDS: acute respiratory distress syndrome. ATRA: all-trans
retinoic acid. CS: cesarean section.
Records identiﬁed through 
PubMed Database searching





Records excluded based on 
review of title and/or abstract
(67 articles)
Full-text assessed for eligibility
(35 articles 154 cases)
Acute respiratory failure due to
other etiologies
(24 articles 142 cases)
Acute respiratory failure due to 
pulmonary edema
(11 articles 12 cases)
Figure 1: The flow diagram of the trial selection process for this literature review.
has been widely used in patients with respiratory failure.
The goal of the use of NPPV is to improve gas exchange,
reduce work of breathing, and avoid endotracheal intubation
and its related complications. Several studies have shown
that NPPV decreases mortality and the need for intuba-
tion in patients with chronic obstructive pulmonary disease
(COPD) exacerbation or cardiogenic pulmonary edema [3,
9]. A meta-analysis showed that early NPPV application
in patients with acute hypoxemic respiratory failure not
associated with COPD or cardiogenic pulmonary edema
may decrease the need for intubation, the length of time
in the ICU, and ICU mortality [10]. However, there are
limited data and evidence regarding NPPVduring pregnancy
thus far. Moreover, according to our literature review, the
majority of cases managed by NPPV during pregnancy
were severe pneumonia due to the 2009 pandemic H1N1
influenza [11, 12]. We excluded these cases due to the lack
of a description of the development of pulmonary edema.
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As shown in Table 2, only 11 studies involving 12 cases
investigated the use of NPPV for pulmonary edema during
pregnancy and postpartum period. Among these reports,
NPPV was administered in three patients with pulmonary
edema caused by preeclampsia, which resulted in positive
maternal outcomes [13–15]. Notably, however, in all three
cases, NPPVwas initiated intraoperatively or postoperatively,
and the prolongation of gestational time was not a primary
goal. By contrast, four studies including five cases reported
that NPPV was implemented before delivery, although the
etiology of pulmonary edema was not preeclampsia. Of
the five cases, three resulted in full-term delivery [16–18],
while two cases of preterm premature rupture of membranes
resulted in prolongation of pregnancy for 2 to 3 days [19].
These cases indicate that NPPV management of pulmonary
edema during pregnancy may contribute to increasing the
gestational period, as long as the maternal and fetal condition
are not exacerbated.
The present case series similarly demonstrated that
NPPV was effective in delaying the delivery for patients
with preeclampsia-induced pulmonary edema. In case 1,
pulmonary edema was well controlled, but labor initiation
became a decisive factor in the termination of pregnancy.
In cases 2 and 3, interestingly, ascites increased gradually,
but pleural effusion did not, demonstrating the efficacy of
NPPV. In addition, we have encountered a case of early
onset preeclampsia complicated by obstructive sleep apnea.
Although the Doppler blood flow study revealed absent
umbilical arterial endodiastolic flow at 22 weeks of ges-
tation, it dramatically improved after the implementation
of NPPV (data not shown). This case might indicate that
NPPV improves maternal oxygenation, thereby contributing
to improved fetal condition in uterus. Diane et al. also
demonstrated that treatment of sleep disordered breathing in
preeclamptic women with nasal CPAP improved fetal activity
[20].
In our four cases, NPPV was implemented without
serious adverse events: no intubation was required, and
no NPPV-related complications, such as aspiration, were
observed. NPPV should be administered in carefully selected
patients during pregnancy and parturition by an experienced
clinician with close monitoring. NPPV is contraindicated
in patients with impaired consciousness or hemodynamic
instability. It should also be avoided in patients who are
uncooperative or unable to protect their airway. Decreased
esophageal sphincter tone, increased gastric pressure, and
delayed gastric emptying due to an enlarged uterus impose
a higher risk of aspiration on pregnant women. Furthermore,
NPPV was applied not only during pregnancy but also after
delivery in the current study. Pulmonary edema can worsen
during the postpartum period by returning blood from the
uterus to central circulation, leading to low colloid oncotic
pressure and increased vascular permeability [21]. Therefore,
close monitoring should be continued along with proper
fluid volume management and respiratory support, which is
necessary in the postpartum period and during pregnancy.
In addition, after the initiation of NPPV for preeclampsia-
induced pulmonary edema, the timing of pregnancy termi-
nation should always be considered. According to our case
series, we advocate making the decision to deliver without
delay once SpO
2
, pleural effusion, subjective dyspnea, or fetal
well-being deteriorates despite NPPVmanagement.
In conclusion, NPPV can be safely administered to
pregnant women with hypoxemic respiratory failure due to
preeclampsia-induced pulmonary edema. NPPV may con-
tribute to an increase in gestational time by stabilizing the
respiratory condition and delaying the timing of delivery.
However, patients should be closely monitored, and the
decision to intubate or terminate the pregnancy should
be made without delay when maternal or fetal condition
worsens.
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